The effects and mechanisms of Gankyrin silencing on reversing the cisplatin resistance of human ovarian cancer SKOV3/DDP cell line

王倩; 程堃

doi:10.3969/j.issn.1007-3969.2014.01.006

您当前的位置：

首页 >

文章列表页 >

The effects and mechanisms of Gankyrin silencing on reversing the cisplatin resistance of human ovarian cancer SKOV3/DDP cell line

更新时间：2025-12-31

- The effects and mechanisms of Gankyrin silencing on reversing the cisplatin resistance of human ovarian cancer SKOV3/DDP cell line
- China Oncology Vol. 24, Issue 1, Pages: 35-40(2014)
- 作者机构：
  
  天津市水阁医院妇产科,天津,300120
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2014.01.006
  CLC：
- Published Online：14 February 2014，
  
  Published：14 February 2014
- 稿件说明：
移动端阅览
王倩,程堃.

王倩, 程堃. The effects and mechanisms of Gankyrin silencing on reversing the cisplatin resistance of human ovarian cancer SKOV3/DDP cell line[J]. China Oncology, 2014, 24(1): 35-40.
王倩,程堃. DOI： 10.3969/j.issn.1007-3969.2014.01.006.

王倩, 程堃. The effects and mechanisms of Gankyrin silencing on reversing the cisplatin resistance of human ovarian cancer SKOV3/DDP cell line[J]. China Oncology, 2014, 24(1): 35-40. DOI： 10.3969/j.issn.1007-3969.2014.01.006.

摘要

背景与目的：卵巢癌是常见的妇科肿瘤，抗肿瘤药耐药性的产生是卵巢癌治疗失败的主要原因之一，Gankyrin基因被认为与肿瘤耐药性密切相关，本文探讨了Gankyrin基因沉默对卵巢癌耐顺铂细胞系SKOV3/DDP顺铂耐药性的逆转作用及机制。方法：应用real-time PCR技术考察Gankyrin在SKOV3和SKOV3/DDP细胞中的表达，应用MTS法检测Gankyrin对SKOV3/DDP细胞顺铂耐受性的影响，应用流式细胞术检测肿瘤细胞凋亡和细胞内罗丹明-123(Rhodamine-123，Rh-123)含量的变化，Western blot和real-time PCR技术检测肿瘤细胞耐药相关蛋白MDR1、Caspase-3/8、Survivin和Bcl-2蛋白表达，Western blot法检测p53、NF-κB和PTEN蛋白表达和AKT磷酸化水平。结果：Gankyrin在SKOV3/DDP细胞中表达升高，沉默Gankyrin基因后可增加SKOV3/DDP细胞对顺铂的敏感性。基因沉默前后耐药逆转倍数(resistant factor，RF)为1.81和2.45，肿瘤细胞中Rh-123含量提高了1.73和2.42倍，细胞凋亡率是对照组的2.23倍和4.23倍，耐药相关蛋白MDR1、Survivin和Bcl-2蛋白水平显著下降，MDR1 mRNA表达是对照组的62.8%和21.6%，Survivin mRNA表达是对照组的24.5%和10.3%，Bcl-2 mRNA表达是对照组的47.5%和18.4%，Caspase-3/8、p53和PTEN表达水平上升，AKT磷酸化和NF-κB水平下降。结论：沉默Gankyrin基因可逆转SKOV3/DDP对顺铂的耐药性，可能与抑制药物外排，促进细胞凋亡有关，PTEN/AKT/NF-κB/p53信号通路可能是其中心环节。

Abstract

Background and purpose: Ovarian cancer is the common gynecological cancer

and the drug resistance of anti-tumor drug was one of major reasons for therapy failure

some studies considered that there is a closed relationship between Gankyrin and drug resistance. In this study

we investigated the effects and mechanisms of Gankyrin silencing on reversing the cisplatin resistance of ovarian cancer drug-resistant SKOV3/DDP cell line. Methods: The expression of Gankyrin in SKOV3 and SKOV3/DDP cells was measured by real-time PCR assay

MTS assay was employed to determine the effect of Gankyrin on SKOV3/DDP sensitivity to cisplatin

apoptosis rate and intracellular concentration of rhodamine-123 (Rh-123) were determined by flow cytometry

the expression of multidrugs resistant protein MDR1

Caspase-3/8

Survivin and Bcl-2 were determined by Western blot and real-time PCR. The phosphorylation of AKT and expression of p53

NF-κB and PTEN were analyzed by Western blot assay. Results: The expression of Gankyrin was increased in SKOV3/DDP cells

Gankyrin silencing was able to increase the cisplatin sensitivity of SKOV3/DDP. Before and after gene silencing

the reverse folds (RF) to cisplatin were 1.81 and 2.45

respectively

the intracellular levels of Rh-123 were 1.73 and 2.42 fold

the apoptosis rates were 2.23 and 4.23 fold

the expressions of MDR1

Survivin and Bcl-2 were downregulated

the mRNA expressions of MDR1 were 62.8% and 21.6%

the mRNA expressions of Survivin were 24.5% and 10.3%

the mRNA expressions of Bcl-2 were 47.5% and 18.4%

the levels of Caspase-3/8

p53 and PTEN were elevated

phosphorylation of AKT and expression of NF-kB were downregulated compared with control group. Conclusion: Gankyrin silencing was able to reverse the cisplatin resistance of SKOV3/DDP cells by inhibiting the drug efflux and promoting cell apoptosis

the PTEN/AKT/NF-κB/p53 may be the key pathway.

关键词

Keywords

references

Views

1928

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Preliminary study on the role and mechanism of ISG15 in exosomes in platinum resistance in ovarian cancer

Progress in treatment of gynecological cancer in 2023

Progress in diagnosis and treatment of mucinous ovarian cancer

The latest progress and prospect of gynecological tumor treatment at 2023 ESMO

Progress in diagnosis and treatment of gynecological tumors in 2022

Related Author

Yanan TIAN

Hui ZHENG

Tianqing YAN

Heng ZHANG

Renquan LU

Lin GUO

Zheng FENG

Qinhao GUO

Related Institution

Department of Clinical Laboratory, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, State Key Laboratory of Genetic Engineering, Fudan University, Institute of Thoracic Oncology, Fudan University, Department of Oncology, Shanghai Medical College, Fudan University

Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital, Fudan University

AI问答

⁰